Etoposid
Etoposid
Klass : C!
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
Celltop, Eposin, Eto-GRY, Etopofos, Etopophos, Etoposid Ebewe, Etoposi......
Celltop, Eposin, Eto-GRY, Etopofos, Etopophos, Etoposid Ebewe, Etoposid Fresenius Kabi, Etoposide Accord, Etoposide Teva, Lastet, Lastet S, VepesidATC-koder
L01CB01
L01CB01Substanser
etoposid, etoposidfosfat
etoposid, etoposidfosfatSammanfattning
Kvinnor har visats ha bättre effekt av etoposid-baserad kombinationsbehandling av småcellig lungcancer än män. Kvinnor är mer benägna att utveckla hematologiska biverkningar och att drabbas av kräkningar. Etoposid ska undvikas till flickor och kvinnor som kan tänkas bli gravida om inte en effektiv preventivmetod används.
Kvinnor har visats ha bättre effekt av etoposid-baserad kombinationsbehandling av småcellig lungcancer än män. Kvinnor är mer benägna att utveckla hematologiska biverkningar och att drabbas av kräkningar. Etoposid ska undvikas till flickor och kvinnor som kan tänkas bli gravida om inte en effektiv preventivmetod används.Background
Generally, women mount stronger innate and adaptive immune responses than men [1]. Women with lung cancer have a more favorable survival compared to men [2]. The 5-year survival is 17 percent among men, and 24 percent among women in Sweden [3]. Visa hela bakgrundstexten
The incidence of lung cancer has decreased among men since from 1980s but has increased significantly among women, which reflects women's changing smoking habits. Now the proportion of smoking women is greater than the proportion of smoking men. In Sweden lung cancer made up 6.1% of all yearly cases of cancer, year 2016. The incidence was higher among women (6.8%, n=2067), compared to men (5.4%, n=1824) [3].
Since chemotherapeutic agents share some adverse effects, evaluation of a particular agent’s sex-related adverse effects during combination chemotherapy is complicated. Another factor that complicates the evaluation of chemotherapeutic treatments’ effect is a poorer prognosis in men compared to women of most oncologic diseases that affects both sexes [4, 5]. For instance female sex is a favorable prognostic factor in small cell lung canc......
Försäljning på recept
Visa hela försäljning på recept
Läkemedel innehållande etoposid (ATC-kod L01CB01) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata [10].
Referenser
Visa referenser
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
Etoposide Accord (etoposid) Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-23, cited 2023-01-12]
Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol. 2000;50(4):315-24.
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-EWING 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22-9.
VAL-databasen. Region Stockholm. 2021 [cited 2023-01-20.]
- Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
- Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
- Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
- Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
- Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
- Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
- Etoposide Accord (etoposid) Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-09-23, cited 2023-01-12]
- Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol. 2000;50(4):315-24.
- Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-EWING 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22-9.
- VAL-databasen. Region Stockholm. 2021 [cited 2023-01-20.]
Uppdaterat
Litteratursökningsdatum: 1/12/2023
Litteratursökningsdatum: 1/12/2023